Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossert, J.
Right arrow Articles by Boffa, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossert, J.
Right arrow Articles by Boffa, J. J.
J Am Soc Nephrol 14:S173-S177, 2003
© 2003 American Society of Nephrology

Supplement Article

Anemia Management and the Delay of Chronic Renal Failure Progression

Jerome Rossert, Bruno Fouqueray and Jean Jacques Boffa

University of Paris VI, Tenon Hospital (AP-HP) and INSERM U489, Paris, France.

Correspondence to Dr. Jerome Rossert, Department of Nephrology and INSERM U489, Tenon Hospital, 4 rue de la Chine, 75020 Paris, France. Phone: 33-1-56-01-60-29; Fax: 33-1-56-01-69-99;

ABSTRACT. Interstitial fibrosis plays a key role in the progression of chronic kidney diseases. Analysis of the biologic effects of erythropoietin and of the pathophysiology of interstitial fibrosis suggest that treatment with epoetin may slow the progression of chronic kidney disease, both by decreasing interstitial fibrosis and by protecting against its consequences. The results of two small prospective studies and of a retrospective one also suggest that treatment with epoetin may have such protective effects. E-mail: jerome.rossert@tnn.ap-hop-paris.fr




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
Y. Furumatsu, Y. Nagasawa, T. Hamano, H. Iwatani, K. Iio, T. Shoji, T. Ito, Y. Tsubakihara, and E. Imai
Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 984 - 990.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
L. De Nicola, G. Conte, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, G. Tirino, D. Avino, F. Catapano, and R. Minutolo
Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 938 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
I. C. Macdougall, R. M. Temple, J. T. C. Kwan, and on behalf of the EPO-GBR-2 Study Group
Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 784 - 793.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. I. Hallan, J. Coresh, B. C. Astor, A. Asberg, N. R. Powe, S. Romundstad, H. A. Hallan, S. Lydersen, and J. Holmen
International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk
J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2275 - 2284.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673